Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

Blood (2016) 128 (14): 1821–1828.

https://doi.org/10.1182/blood-2016-07-726729

Published: 2016

Includes: Supplemental data

Journal Articles

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)

Torben Plesner, MD, Hendrik-Tobias Arkenau, Peter Gimsing, Jakub Krejcik, Charlotte Lemech, Monique C. Minnema, Ulrik Lassen, Jacob P. Laubach, MD, Antonio Palumbo, Steen Lisby, Linda Basse, Jianping Wang, A Kate Sasser, Mary E Guckert, Howard Yeh, Tahamtan Ahmadi, Henk M. Lokhorst, Paul G. Richardson

Blood (2015) 126 (23): 507.

https://doi.org/10.1182/blood.V126.23.507.507

Published: 2015

Journal Articles

Health-Related Quality of Life and Patient-Reported Outcomes in Patients Receiving Ofatumumab in Combination with Fludarabine and Cyclophosphamide (FC) Versus FC Alone in the Complement 2 Trial

Tadeusz Robak, MD Professor, Krzysztof Warzocha, MD PhD, K Govind Babu, Yaroslav Kulyaba, Kazimierz Kuliczkowski, Kudrat Abdulkadyrov, MD PhD, Javier Loscertales, Iryna Kryachok, Janusz Kloczko, Grygoriy Rekhtman, Wojciech Homenda, Jerzy Blonski, Astrid McKeown, PhD, Chai-Ni Chang, Stephanie C Manson, Steen Lisby, Ira V. Gupta, MD, Sebastian Grosicki, MD PhD

Blood (2015) 126 (23): 5288.

https://doi.org/10.1182/blood.V126.23.5288.5288

Published: 2015

Journal Articles

Ofatumumab (OFA) Vs. Physician’s Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study OMB114242

Anders Österborg, Miklós Udvardy, Andrey Zaritskey, Per-Ola Andersson, Sebastian Grosicki, Grzegorz Mazur, Polina Kaplan, Michael Steurer, Anna Schuh, Marco Montillo, Iryna Kryachok, Jan Moritz Middeke, Yaroslav Kulyaba, Grygoriy Rekhtman, Michele Gorczyca, Siobhan Daly, Chang Chai-Ni, Steen Lisby, Ira Gupta

Blood (2014) 124 (21): 4684.

https://doi.org/10.1182/blood.V124.21.4684.4684

Published: 2014

Journal Articles

Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma

Torben Plesner, MD, Hendrik-Tobias Arkenau, MD, Henk M. Lokhorst, MDPhD, Peter Gimsing, MD PhD, Jakub Krejcik, MD, Charlotte Lemech, MD, Monique C. Minnema, MDPhD, Ulrik Lassen, MDPhD, Jacob P. Laubach, MD, Tahamtan Ahmadi, MD PhD, Howard Yeh, MD, Mary E Guckert, MSN, RN, Huaibao Feng, Nikolai Constantin Brun, MDPhD, Steen Lisby, Linda Basse, MDDMSc, Antonio Palumbo, MD, Paul G. Richardson

Blood (2014) 124 (21): 84.

https://doi.org/10.1182/blood.V124.21.84.84

Published: 2014

Journal Articles

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Gustaaf W van Imhoff, MD PhD, Andrew McMillan, Matthew J. Matasar, MD MS, John Radford, MD FRCP, Kirit M Ardeshna, MD FRCPath, Kazimierz Kuliczkowski, WonSeog Kim, Xiaonan Hong, Jette Soenderskov Goerloev, Andrew Davies, María Dolores Caballero Barrigón, Michinori Ogura, MD PhD, Michael Fennessy, PhD, Qiming Liao, PhD, Bronno van der Holt, PhD, Steen Lisby, Thomas S. Lin, MD PhD, Anton Hagenbeek, MD PhD

Blood (2014) 124 (21): 630.

https://doi.org/10.1182/blood.V124.21.630.630

Published: 2014

Journal Articles

Ofatumumab (OFA) Maintenance Prolongs PFS in Relapsed CLL: Prolong Study Interim Analysis Results

Marinus H.J. van Oers, Kazimierz Kuliczkowski, MD PhD Prof., Lukas Smolej, Mario Petrini, Fritz Offner, Sebastian Gorsicki, Mark-David Levin, Ira Gupta, Jennifer Phillips, Vanessa Williams, Steen Lisby, Christian Geisler

Blood (2014) 124 (21): 21.

https://doi.org/10.1182/blood.V124.21.21.21

Published: 2014

Journal Articles

Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911)

Peter Hillmen, MB ChB, PhD, Tadeusz Robak, Ann Janssens, MD, K Govindbabu, MD, Sebastian Grosicki, MD, Jiri Mayer, MD, PhD, Panagiotis Panagiotidis, MD, Eva Kimby, MD, Anna Schuh, MD, Thomas Boyd, MD, Marco Montillo, MD, Astrid McKeown, PhD, Jodi L Carey, RN, BSN, Ira V Gupta, MD, Chai-Ni Chang, MS, Steen Lisby, MD, DMSc, Fritz Offner, MD

Blood (2013) 122 (21): 528.

https://doi.org/10.1182/blood.V122.21.528.528

Published: 2013

Journal Articles

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma

Matthew J. Matasar, Myron S. Czuczman, Maria Alma Rodriguez, Michael Fennessy, Thomas C. Shea, Gary Spitzer, Izidore S. Lossos, Mohamed A. Kharfan-Dabaja, Robin Joyce, Luis Fayad, Kristen Henkel, Qiming Liao, Klaus Edvardsen, Roxanne C. Jewell, Doug Fecteau, Rajendra P. Singh, Steen Lisby, Craig H. Moskowitz

Blood (2013) 122 (4): 499–506.

https://doi.org/10.1182/blood-2012-12-472027

Published: 2013

Journal Articles

Ofatumumab (OFA) in Combination with CHOP for Previously Untreated Follicular Lymphoma: Follow-up Results

Myron S. Czuczman, MD, Georg Hess, Ole Gadeberg, Lars Moeller Pedersen, Per Hansen, David Belada, M.D., Ph.D., Stephanie A. Gregory, MD, Brad Pohlman, MD, Jiri Mayer, M.D., PhD., Prof., Robert Pytlik, Lorenz Trumper, Andreas Viardot, MD, Ira V. Gupta, MD, Thomas S. Lin, MD, PhD, Paul Winter, Nancy Goldstein, Roxanne C. Jewell, PhD, Steen Lisby, MD, DMSc

Blood (2012) 120 (21): 1632.

https://doi.org/10.1182/blood.V120.21.1632.1632

Published: 2012

Journal Articles

Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study

Torben Plesner, MD, Henk Lokhorst, MD, PhD, Peter Gimsing, MD, PhD, Hareth Nahi, Steen Lisby, MD, DMSc, Paul G. Richardson, MD

Blood (2012) 120 (21): 73.

https://doi.org/10.1182/blood.V120.21.73.73

Published: 2012

Journal Articles

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study

Blood (2012) 119 (16): 3698–3704.

https://doi.org/10.1182/blood-2011-09-378323

Published: 2012

Includes: Supplemental data

Journal Articles

A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia,

Richard R. Furman, MD, Herbert Eradat, MD, MS, Christine Gabriella DiRienzo, BS, PhD, Suzanne R Hayman, MD, Craig C. Hofmeister, MD, Nathalie A. Avignon, BA, John P. Leonard, MD, Morton Coleman, MD, Ranjana Advani, MD, Julie C. Switzky, RN, MSN, MBA, Qiming Liao, PhD, Damini N. Shah, Steen Lisby, MD, DMSc, Thomas S Lin, MD, PhD

Blood (2011) 118 (21): 3701.

https://doi.org/10.1182/blood.V118.21.3701.3701

Published: 2011

Journal Articles

A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT)

Matthew J. Matasar, MD, MS, Myron S. Czuczman, MD, Maria Alma Rodriguez, MD, Michael Fennessy, BSc, PhD, Thomas C. Shea, MD, Gary Spitzer, MD, Izidore S Lossos, MD, Mohamed A. Kharfan-Dabaja, MD, Robin Joyce, MD, Luis Fayad, MD, Qiming Liao, PhD, Klaus Edvardsen, MD, PhD, Steen Lisby, MD, DMSc, Craig H. Moskowitz, MD

Blood (2011) 118 (21): 957.

https://doi.org/10.1182/blood.V118.21.957.957

Published: 2011

Journal Articles

A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma – Preliminary Safety Data

Peter Gimsing, MD, DMSci, Assoc. Prof., Torben Plesner, MD, Hareth Nahi, Henk Lokhorst, MD, PhD, Marie-Louise Valentin, MD, Steen Lisby, MD, DMSc, Paul G. Richardson, MD

Blood (2011) 118 (21): 1873.

https://doi.org/10.1182/blood.V118.21.1873.1873

Published: 2011

Journal Articles

Correlations Between Ofatumumab Exposure and Treatment Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy

William G. Wierda, MD, PhD, Roxanne C. Jewell, PhD, Thomas J. Kipps, M.D., Ph.D, Jan Dürig, MD, Laimonas Griskevicius, Stephan Stilgenbauer, MD, Lukas Smolej, M.D., Ph.D., Georg Hess, Francisco J. Hernandez-Ilizaliturri, MD, Swaminathan Padmanabhan, MBBS, MD, Lei Fang, Michele M. Gorczyca, MS, Geoffrey W. Chan, MD, Ira V. Gupta, MD, Steen Lisby

Blood (2011) 118 (21): 1793.

https://doi.org/10.1182/blood.V118.21.1793.1793

Published: 2011

Journal Articles

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

William G. Wierda, Swaminathan Padmanabhan, Geoffrey W. Chan, Ira V. Gupta, Steen Lisby, Anders Österborg, for the Hx-CD20-406 Study Investigators

Blood (2011) 118 (19): 5126–5129.

https://doi.org/10.1182/blood-2011-04-348656

Published: 2011

Journal Articles

Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia

Blood (2010) 116 (21): 921.

https://doi.org/10.1182/blood.V116.21.921.921

Published: 2010

Journal Articles

Ofatumumab Monotherapy for Treatment of Patients with Relapsed/Progressive Diffuse Large B-Cell Lymphoma: Results From a Multicenter Phase II Study

Bertrand Coiffier, MD, PhD, André Bosly, MD, Ka Lung Wu, MD, PhD, Gregor Verhoef, MD, PhD, Van Eygen Koen, MD, Giovanni Martinelli, MD, Gabriela Barca, MD, PhD, Andrew Davies, MRCP, PhD, Eve Gallop-Evans, PhD, Swaminathan Padmanabhan, MBBS, MS, Ira V. Gupta, MD, Thomas S. Lin, MD, PhD, Randy L. Davis, DrPH, Nedjad Losic, MSC, Steen Lisby, MD, DMSC, John A. Radford, MD

Blood (2010) 116 (21): 3955.

https://doi.org/10.1182/blood.V116.21.3955.3955

Published: 2010

Journal Articles

A Phase II Trial of Ofatumumab In Subjects with Waldenstrom's Macroglobulinemia.

Richard R. Furman, MD, Herbert Eradat, MD, MS, Julie C. Switzky, RN, MSN, MBA, Suzanne R. Hayman, MD, Craig C. Hofmeister, MD, Nathalie A. Avignon, BA, John P. Leonard, MD, Morton Coleman, MD, Qiming Liao, PhD, Damini N. Shah, Stephanie Brownell-Buttich, BFA, Steen Lisby, MD, DMSC, Thomas S. Lin, MD, PhD

Blood (2010) 116 (21): 1795.

https://doi.org/10.1182/blood.V116.21.1795.1795

Published: 2010

NARROW

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)

Health-Related Quality of Life and Patient-Reported Outcomes in Patients Receiving Ofatumumab in Combination with Fludarabine and Cyclophosphamide (FC) Versus FC Alone in the Complement 2 Trial

Ofatumumab (OFA) Vs. Physician’s Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study OMB114242

Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Ofatumumab (OFA) Maintenance Prolongs PFS in Relapsed CLL: Prolong Study Interim Analysis Results

Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911)

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma

Ofatumumab (OFA) in Combination with CHOP for Previously Untreated Follicular Lymphoma: Follow-up Results

Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study

A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia,

A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT)

A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma – Preliminary Safety Data

Correlations Between Ofatumumab Exposure and Treatment Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia

Ofatumumab Monotherapy for Treatment of Patients with Relapsed/Progressive Diffuse Large B-Cell Lymphoma: Results From a Multicenter Phase II Study

A Phase II Trial of Ofatumumab In Subjects with Waldenstrom's Macroglobulinemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only